rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2009-676rsp-813Research ArticleСтатьиArticlesПрименение Энбрела у больных анкилозирующим спондилитомEtanercept (enbrel) administration in patients with ankylosing spondylitisБочковаА. Г.BochkovaA G-200915122009476№6 (2009)6165Copyright © Бочкова А.Г., 20092009Бочкова А.Г.Bochkova A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/813

Этанерцепт (ЭТЦ, Энбрел) – димерный человеческий растворимый рецептор р75 фактора некроза опухолей (ФНО), соединенный с Fc-фрагментом человеческого иммуноглобулина G1 (IgG1). Этанерцепт был зарегистрирован для применения у пациентов анкилозирующим спондилитом (АС) в США в 2003 г. и в странах Европейского Союза в 2004 г. В России препарат зарегистрирован летом2009 г. под торговым названием Энбрел. Для оценки эффективности и переносимости ЭТН было проведено 5 многоцентровых рандомизированных плацебо-контролируемых клинических исследований (РКИ) [1,2,3,4]

References<div><p>Gorman J.D., Sack K.E., Davis J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med., 2002, 346,1349-56.</p><p>Brandt J., Khariouzov A., Listing J. et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum., 2003, 48,1667-75.</p><p>Calin A, Dijkmans B.A.C., Emery P. et al. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis., 2004, 63, 1594-1600.</p><p>Davis J.C., van der Heijde D., Braun J. et al. Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis. Artritis Rheum., 2003, 48, 3230-36.</p><p>Anderson J.J., Baron G., van der Ytijde et al. Ankylosing Spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum., 44,1876-86.</p><p>Davis J.C., van der Heijde D., Braun J. et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 week. Ann Rheum Dis., 2005, 64, 1557-62.</p><p>Davis J.C., van der Heijde D., Braun J. et al. Efficacy and safety of up to 192 weeks of of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis., 2008, 67 346-52.</p><p>Braun J., McHugh N., Singh A. et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice weekly. Rheumatology, 2007, 46, 999-1004.</p><p>Brandt J., Khariouzov A., Listing J. et al. Successful short term treatment of patients with severe undifferentiated spondyloArthritisitis with the anti-tumor necrosis factor-a fusion receptor protein etanercept. J. Rheumatol., 2004, 31, 531–38</p><p>Inman R.D., Clegg D.O., Davis J.C. et al. Etanercept in adult patients with early onset ankylosing spondylitis. J. Rheumatol., 2006, 33, 1634-36.</p><p>de Vries V.R., van der Horst-Bruinsma I.E., Nurmoohamed M.T. et al. Immunogenity does not influence treatment wiyh etanercept in patients with ankylosing spondylitis (AS). Ann. Rheum. Dis., 2008, 28 Mar, epub of print.</p><p>Gonnet-Gracia C., Barneche T., Richez C. et al. Anti- nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid Arthritisitis and ankylosing spondylitis treated with TNF-alpha blockers. Clin. Exp. Rheumatol., 2008, 26(3), 401-7</p><p>Kruithof E., Rycke L.D., Roth J. et al. Immuno- modulatory effect of etanercept on peripheral Joint synovitis in the spondyloarthropaties. Arthr. Rheum., 2005,52,3898-909.</p><p>Guignard S., Grossec L., Salliot C. et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in spondylArthritisopathy patients : a retrospective study. Ann Rheum Dis., 2006, doi:10.1136/ard.</p><p>Carmona L. Gomes-Reino J.J., Biobadaser group. Survival of TNF antagonists in spondylarthrioparthy is better than in rheumatoid Arthritisitis. Data from the Spanish registry BIOBADASER. Arthritis Res. Ther., 2006, 8, R72 (doi:10.1186/ar1941).</p><p>Lyndell L.Lim, Fraunfelder F.W., Rosenbaum J.T. Do Tumor Necrosis Factor Ingibitors Cause Uveitis. Arthritis Rheum, 2007, 56, 3248-52.</p><p>Braun J., Baraliakos X., Listing J. et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum., 2005,52,2447–51.</p><p>Braun J., Baraliakos X., Listing J. et al. Differences in the incidence of flare or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor &amp; agents. Arthritis Rheum., 2007,57,639-47.</p><p>Baraliakos X., Listing J., Brandt J. et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum., 2005, 52, 1216-23.</p><p>van der Heijde D., Landewe R., Ory P. et al. Twoyears etanercept therapy does not inhibit radiographic 65 progression in patient with ankylosing spondylitis. Ann. Rheum. Dis.,65 (suppl II),81</p><p>Baraliakos X., Brandt J., Listing Jet al. Outcome of patients with active ankylosing spondylitisafter two years of therapy with etanercept clinical and magnetic resonance imaging study. Arthritis Rheum., 2005, 53, 856-63.</p><p>Baraliakos X., Davis J., Tsuji W., Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum., 2005, 52,1216–23.</p><p>Delaunay C., Farrenj V., Marini-portugal A. et al. Infliximab to etanercept switch in patients with spondyloarthritisopaties and psoriatic arthritis: preliminary data. J. Rheumatol., 2005, 32(11), 2183-5</p><p>Salaffi F., Carotti M., Gagofalo G., et al. Radiological scoring methods for Ankylosing Spondylitis: a comparison between the Bath Ankylosing Spondylitis Spine Score. Clin. Exp. Rheumatol., 2007,25,67-74.</p><p>van der Heijde D., Landewe R., Einstein S., et al. Radiographic progression of Ankylosing Spondylitis after up two years of treatment with etanercept. Arthritis Rheum.,2008, 58,5, 1324-31.</p><p>Braun J., Baraliakos X., Golder W. et al. Listing J. et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum., 2003, 48, 1126–36.</p></div><br /><div><p>Gorman J.D., Sack K.E., Davis J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med., 2002, 346,1349-56.</p><p>Brandt J., Khariouzov A., Listing J. et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum., 2003, 48,1667-75.</p><p>Calin A, Dijkmans B.A.C., Emery P. et al. Outcomes of a multicentre randomized clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis., 2004, 63, 1594-1600.</p><p>Davis J.C., van der Heijde D., Braun J. et al. Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis. Artritis Rheum., 2003, 48, 3230-36.</p><p>Anderson J.J., Baron G., van der Ytijde et al. Ankylosing Spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum., 44,1876-86.</p><p>Davis J.C., van der Heijde D., Braun J. et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 week. Ann Rheum Dis., 2005, 64, 1557-62.</p><p>Davis J.C., van der Heijde D., Braun J. et al. Efficacy and safety of up to 192 weeks of of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis., 2008, 67 346-52.</p><p>Braun J., McHugh N., Singh A. et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice weekly. Rheumatology, 2007, 46, 999-1004.</p><p>Brandt J., Khariouzov A., Listing J. et al. Successful short term treatment of patients with severe undifferentiated spondyloArthritisitis with the anti-tumor necrosis factor-a fusion receptor protein etanercept. J. Rheumatol., 2004, 31, 531–38</p><p>Inman R.D., Clegg D.O., Davis J.C. et al. Etanercept in adult patients with early onset ankylosing spondylitis. J. Rheumatol., 2006, 33, 1634-36.</p><p>de Vries V.R., van der Horst-Bruinsma I.E., Nurmoohamed M.T. et al. Immunogenity does not influence treatment wiyh etanercept in patients with ankylosing spondylitis (AS). Ann. Rheum. Dis., 2008, 28 Mar, epub of print.</p><p>Gonnet-Gracia C., Barneche T., Richez C. et al. Anti- nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid Arthritisitis and ankylosing spondylitis treated with TNF-alpha blockers. Clin. Exp. Rheumatol., 2008, 26(3), 401-7</p><p>Kruithof E., Rycke L.D., Roth J. et al. Immuno- modulatory effect of etanercept on peripheral Joint synovitis in the spondyloarthropaties. Arthr. Rheum., 2005,52,3898-909.</p><p>Guignard S., Grossec L., Salliot C. et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in spondylArthritisopathy patients : a retrospective study. Ann Rheum Dis., 2006, doi:10.1136/ard.</p><p>Carmona L. Gomes-Reino J.J., Biobadaser group. Survival of TNF antagonists in spondylarthrioparthy is better than in rheumatoid Arthritisitis. Data from the Spanish registry BIOBADASER. Arthritis Res. Ther., 2006, 8, R72 (doi:10.1186/ar1941).</p><p>Lyndell L.Lim, Fraunfelder F.W., Rosenbaum J.T. Do Tumor Necrosis Factor Ingibitors Cause Uveitis. Arthritis Rheum, 2007, 56, 3248-52.</p><p>Braun J., Baraliakos X., Listing J. et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti–tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum., 2005,52,2447–51.</p><p>Braun J., Baraliakos X., Listing J. et al. Differences in the incidence of flare or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor &amp; agents. Arthritis Rheum., 2007,57,639-47.</p><p>Baraliakos X., Listing J., Brandt J. et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum., 2005, 52, 1216-23.</p><p>van der Heijde D., Landewe R., Ory P. et al. Twoyears etanercept therapy does not inhibit radiographic 65 progression in patient with ankylosing spondylitis. Ann. Rheum. Dis.,65 (suppl II),81</p><p>Baraliakos X., Brandt J., Listing Jet al. Outcome of patients with active ankylosing spondylitisafter two years of therapy with etanercept clinical and magnetic resonance imaging study. Arthritis Rheum., 2005, 53, 856-63.</p><p>Baraliakos X., Davis J., Tsuji W., Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum., 2005, 52,1216–23.</p><p>Delaunay C., Farrenj V., Marini-portugal A. et al. Infliximab to etanercept switch in patients with spondyloarthritisopaties and psoriatic arthritis: preliminary data. J. Rheumatol., 2005, 32(11), 2183-5</p><p>Salaffi F., Carotti M., Gagofalo G., et al. Radiological scoring methods for Ankylosing Spondylitis: a comparison between the Bath Ankylosing Spondylitis Spine Score. Clin. Exp. Rheumatol., 2007,25,67-74.</p><p>van der Heijde D., Landewe R., Einstein S., et al. Radiographic progression of Ankylosing Spondylitis after up two years of treatment with etanercept. Arthritis Rheum.,2008, 58,5, 1324-31.</p><p>Braun J., Baraliakos X., Golder W. et al. Listing J. et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum., 2003, 48, 1126–36.</p></div><br />

The authors declare that there are no conflicts of interest present.